Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company developing innovative cancer therapies, primarily focused on Plinabulin, a novel small molecule with immunomodulating and anti-cancer properties. Plinabulin targets advanced non-small cell lung cancer and chemotherapy-induced neutropenia, enhancing immune response and safety. BeyondSpring also advances small molecule immuno-oncology agents and holds a stake in SEED Therapeutics, which develops targeted protein degradation drugs for oncology and CNS diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.